Abstract
We have completed a double-blind parallel group comparison of the 5-HT2 receptor antagonist ketanserin with placebo in 22 hypertensive patients. Ketanserin (20-40 mg twice daily) lowered sitting blood pressure more than placebo by 6.9 mm Hg systolic (NS), 13.1 mm Hg diastolic (P less than 0.05) and by 11.4 mm Hg mean arterial pressure (P less than 0.02). The fall in standing blood pressure was similar and we observed no first dose hypotensive effect. Ketanserin lowered the sitting heart rate by 11.1 beats/min (P less than 0.01). The drug was well tolerated.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andrén L., Svensson A., Dahlöf B., Eggertsen R., Hansson L. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist. Acta Med Scand. 1983;214(2):125–130. [PubMed] [Google Scholar]
- Ball S. G., Zabludowski J. R., Robertson J. I. Mechanism of antihypertensive action of ketanserin in man. Br Med J (Clin Res Ed) 1983 Oct 8;287(6398):1065–1065. doi: 10.1136/bmj.287.6398.1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- De Cree J., Verhaegen H., Symoens J. Acute blood-pressure-lowering effect of ketanserin. Lancet. 1981 May 23;1(8230):1161–1162. doi: 10.1016/s0140-6736(81)92331-x. [DOI] [PubMed] [Google Scholar]
- Fagard R., Fiocchi R., Lijnen P., Staessen J., Moerman E., de Schaepdryver A., Amery A. Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J. 1984 Feb;51(2):149–156. doi: 10.1136/hrt.51.2.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hedner T., Persson B., Berglund G. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension. Br J Clin Pharmacol. 1983 Aug;16(2):121–125. doi: 10.1111/j.1365-2125.1983.tb04974.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Leysen J. E., Awouters F., Kennis L., Laduron P. M., Vandenberk J., Janssen P. A. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981 Mar 2;28(9):1015–1022. doi: 10.1016/0024-3205(81)90747-5. [DOI] [PubMed] [Google Scholar]
- Persson B., Hedner T., Berglund G. Ketanserin in essential hypertension: effects during rest and exercise. Eur J Clin Pharmacol. 1983;25(3):307–312. doi: 10.1007/BF01037939. [DOI] [PubMed] [Google Scholar]
- Reimann I. W., Frölich J. C. Mechanism of antihypertensive action of ketanserin in man. Br Med J (Clin Res Ed) 1983 Aug 6;287(6389):381–383. doi: 10.1136/bmj.287.6389.381-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wenting G. J., Man in 't Veld A. J., Woittiez A. J., Boomsma F., Schalekamp M. A. Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. Br Med J (Clin Res Ed) 1982 Feb 20;284(6315):537–539. doi: 10.1136/bmj.284.6315.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wenting G. J., Woittiez A. J., Man in't Veld A. J., Schalekamp M. A. 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension. 1984 Jan-Feb;6(1):100–109. doi: 10.1161/01.hyp.6.1.100. [DOI] [PubMed] [Google Scholar]